AZ vs. Clovis...who will win?

Discussion in 'AstraZeneca' started by anonymous, Sep 12, 2015 at 9:40 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    So, based on data, Rociletinib and AZD9291 look pretty similar as far as efficacy. Maybe some tolerability differences. Two different organizations promoting the products...who will win and why?
     

  2. anonymous

    anonymous Guest

    AZ hands down. They will simply buy the KOL's and the managed care companies. Efficacy has nothing to do with it. End of discussion.
     
  3. anonymous

    anonymous Guest

    Too funny, AZ can't launch an oncology drug. AZ MAPS is a laughing stock and KOL's are on the Clovis bandwagon, just listen to Research to Practice, the boat has sailed on AZ, you've already lost, you just don't know it.
     
  4. anonymous

    anonymous Guest

    The account directors here are for the most part just made up of one never has-been after another. They have zero relationships or skills to be able to get anything new onto a payer formulary anyway to position it above competition. Clovis will easily walk away with the win even if they hit the market after AZ. That combined with the ones that set up the distribution models that are not even close to par with a competitor makes for a uphill climb with no summit to be attainable anyway. Sad but true. Recipe for failure because most of the ingredients are non applicable to an even remote chance of success.
     
  5. anonymous

    anonymous Guest

    Could be analogous to David vs Goliath. Small biotech vs Big Pharma. Advantages and disadvantages on both sides. In the end, the fast and nimble could win.
     
  6. anonymous

    anonymous Guest

    Oh great! Now we have to worry about ILD ....sucks for patients and sucks for AZ..we can't seem to get out of our way in clinical trials...wtf. Clovis is probably licking their chops.
     
  7. anonymous

    anonymous Guest

    I am going to contact Clovis to see if they are going to hire a sales team once they get approval. Could be a great opportunity here!
     
  8. anonymous

    anonymous Guest

    why on earth would we do combo studies if ILD was this much of a problem? 6/23 patients getting ILD? AZ needs to stick to monotherapy where we have solid data. No way a small start-up should beat us in two products, but AZ must own Lung first.

    Is Clovis in the field yet?
     
  9. anonymous

    anonymous Guest

    Nice try.